X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cymerus mesenchymal stem cells
Therapeutic Area: Podiatry Product Name: CYP-006TK
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cymerus mesenchymal stem cell
Therapeutic Area: Podiatry Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
